Day: February 15, 2024

Saratoga Investment Corp. Increases Quarterly Dividend by $0.01, or 1.4%, to $0.73 per Share for the Fiscal Fourth Quarter Ended February 29, 2024

Written by Customer Service on February 15, 2024. Posted in Dividend Reports And Estimates.

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that its Board of Directors has declared a quarterly dividend of $0.73 per share for the fiscal fourth quarter ended February 29, 2024, an increase of $0.01 from $0.72 per share in the prior fiscal third quarter, and the sixteenth quarterly dividend increase in a row. Total dividends for fiscal year 2024 are $2.85 per share, an increase of 16.8% over the prior year. This fourth quarter dividend is payable on March 28, 2024, to all stockholders of record at the close of business on March 13, 2024. “We continue to benefit from the elevated level of interest rates on our largely floating rate assets combined with the growth of our overall portfolio in well-selected...

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

Written by Customer Service on February 15, 2024. Posted in Public Companies.

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection. Anaphylm candidate, with the potential to be the first and only non-invasive, orally delivered epinephrine product, demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of severe allergic reactions, including anaphylaxis. A Phase 3 pivotal study for Anaphylm is currently underway with topline data anticipated in the first quarter of 2024.WARREN, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’...

Gray Television Launches InvestigateTV+ en Español to Serve Extended Bilingual Audience in 26 Gray-Owned Telemundo Markets

Written by Customer Service on February 15, 2024. Posted in Public Companies.

Mendoza 1Luis Carlos MendozaATLANTA, Feb. 15, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray”) (NYSE: GTN) announces the launch of InvestigateTV+ en Español on February 26, 2024, in 26 of Gray’s Telemundo markets. The program from Gray’s award-winning investigative team, which currently airs in English in 113 of Gray’s markets, will now reach an extended audience through its newly formatted show in Spanish. Airing Monday through Friday in early news windows across the country, the show will provide in-depth, informative, and inspirational stories in Spanish that aim to dig deeper into storytelling while providing viewers with solutions.“An essential part of Gray’s mission is investigative journalism, and it is our goal for everyone to see it. Whether a viewer speaks Spanish or English, we want to give viewers the...

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Written by Customer Service on February 15, 2024. Posted in Public Companies.

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research...

LegalZoom Expands Largest Grant Program To-Date to Deploy $3 Million to Small Business Owners as Part of Fast Break for Small Business Program With the NBA

Written by Customer Service on February 15, 2024. Posted in Public Companies.

NBA Champion and Two-time MVP Giannis Antetokounmpo and Two-time WNBA Champion Kelsey Plum team up with LegalZoom to support the small business community and share LegalZoom’s best plays for entrepreneursGiannis Antetokounmpo partners with LegalZoomNBA Champion and two-time MVP, Giannis Antetokounmpo partners with LegalZoom today to announce that applications are open for the annual Fast Break for Small Business grant program.MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — LegalZoom.com, Inc. (Nasdaq: LZ), the No. 1 choice in online small business formations, today announced that applications are open for the last round of the annual Fast Break for Small Business grant program in partnership with the NBA, WNBA and NBA G-League. This season will mark the program’s largest grant cohort to date with a campaign to...

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on February 15, 2024. Posted in Earnings Releases And Operating Results.

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast...

Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2023

Written by Customer Service on February 15, 2024. Posted in Earnings Releases And Operating Results.

~ Strong 4Q and Full Year sales and profit increase versus last year ~ ~ Expect 9% to 11% sales growth in 2024 with expanding margins ~ PLANO, Texas, Feb. 15, 2024 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and twelve months ended December 31, 2023. Unless otherwise stated, all results and comparisons are from continuing operations. Fourth Quarter 2023 Financial Results (compared to fourth quarter 2022, except as noted)Sales increased 11% to $413 million. GAAP income from continuing operations increased $9 million to $26 million, an increase of 54%. Adjusted net income increased $10 million to $47 million, an increase of 28%. GAAP operating income increased $7 million to $44 million, an increase of 18%. Adjusted operating...

Where Food Comes From, Inc. Reports 2023 Fourth Quarter and Full Year Financial Results

Written by Customer Service on February 15, 2024. Posted in Earnings Releases And Operating Results.

Fourth Quarter Highlights – 2023 vs. 2022Verification and certification revenue up 17% to $5.5 million from $4.7 million Product sales flat at $0.9 million Total revenue up 10% to $6.7 million from $6.1 million Net income increased 58% to $776,000 from $490,000 Diluted EPS increased to $0.14 from $0.08 Adjusted EBITDA up 31% to $1.3 million from $1.0 million Company buys back more than $1.0 million of its stock in Q4Full-Year Highlights – 2023 vs. 2022Verification and certification revenue up 10% to $19.4 million from $17.6 million Product sales decline 8% to $4.0 million from $4.4 million Total revenue up slightly to $25.1 million from $24.8 million Net income increases 8% to $2.2 million from $2.0 million Diluted EPS of $0.39 vs. $0.33 Adjusted EBITDA flat at $3.8 million Cash generated from operations increased to $2.8 million...

Navios South American Logistics Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2023

Written by Customer Service on February 15, 2024. Posted in Earnings Releases And Operating Results.

Revenue$85.3 million in Q4 2023 $310.8 million in FY 2023Profit$3.2 million in Q4 2023 $13.8 million in FY 2023Adjusted EBITDA, a Non-IFRS measure$35.2 million in Q4 2023 $123.8 million in FY 2023MONTEVIDEO, Uruguay, Feb. 15, 2024 (GLOBE NEWSWIRE) — Navios South American Logistics Inc. (“Navios Logistics” or the “Company”), one of the largest infrastructure and logistics companies in the Hidrovia region of South America, today reported its financial results for the fourth quarter and year ended December 31, 2023. Angeliki Frangou, Chairwoman, stated “We are pleased with the results for 2023. Our adjusted EBITDA increased by 30% compared to 2022. The region continues to grow at a healthy pace, and all of our segments are expected to continue to perform well. For 2024, about 75% of our dry barge convoys’...

Global Rehabilitation Equipment Market to Surpass 24.28 Billion by 2030 Driven by Expanding Emphasis on Home Healthcare

Written by Customer Service on February 15, 2024. Posted in Mergers And Acquisitions.

SkyQuest projects that the global rehabilitation equipment market will attain a value of USD24.28 billion by 2030, with a CAGR of 6.1% during the forecast period (2023-2030). The global rehabilitation equipment market is witnessing substantial growth, driven by various compelling factors. Rehabilitation equipment encompasses multiple devices and tools designed to support individuals in their physical recovery journey, ultimately enhancing their quality of life following an illness, injury, or surgical procedure. Westford,USA, Feb. 15, 2024 (GLOBE NEWSWIRE) — According to SkyQuest, the global rehabilitation equipment market is currently presented with a significant opportunity for growth due to the expanding emphasis on home healthcare and telehealth services. This trend has paved the way for development of portable and user-friendly...

Day: February 15, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice